CE Education

In order to successfully develop targeted treatment plans and meet the clinical and disease needs of individual patients with acute myeloid leukemia (AML), one must understand the key safety and efficacy data. This activity will focus on practical expert recommendations for optimizing the use of new and recently approved agents and regimens. Hear from three experts as they review the most appropriate therapeutic strategies for individual patients.

This activity was previously presented as a webinar with live Q&A in June and early July of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation, Helsinn, and Pfizer, Inc.

The current paradigm of AML treatment involves two phases, intensive induction chemotherapy with the goal of inducing a complete remission, followed by consolidation in hopes to deepen the response and try to eradicate any residual disease that remains. In this interview, we discuss how maintenance therapy may be incorporated into this current treatment paradigm. Read on and review how Dr. Kadia explains how maintenance therapy could shift the paradigm and which patients are likely to benefit. He will describe the role of hypomethylating agents in maintenance therapy and the significance of CC-486, an oral azacitidine, currently in clinical trials.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

In recent years, AML has been characterized from molecular perspectives and with identifications of recurrent mutations. The standard of care for our older patients with AML is rapidly evolving. There are a number of new combinations and FDA approvals available for use today in our patients. Our increasing understanding of AML biology is leading to further rational drug development and effective targeted agents. In the past three years we have been fortunate to have eight new drugs FDA approved across the spectrum of disease. In today’s presentation, Dr. Jonas will also focus specifically on the mechanism of action and novel targets of BCL-2 and a SMO inhibitor, providing you with an overview of safety and efficacy as reported in clinical trials.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

In this activity, Dr. Pollyea will outline the clinical imperative for mutational testing for IDH mutations during prognosis of AML and the implications of IDH1 and IDH2 mutations on prognosis and treatment selection. He will share the latest data which compare and contrast trial endpoints of elimination of minimal residual disease versus mutational clearance and relate each to its clinical impact in newly diagnosed AML patients. In addition, Dr. Pollyea will report on promising clinical trials of IDH1 and IDH2 inhibitors for AML, both alone and in combination with other therapies in the frontline setting.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

In this activity, Dr. Atallah explains the mechanism of action and emerging role of HDAC inhibitors in the treatment of acute myeloid leukemia. In his interview, Dr. Atallah answers questions regarding emerging data and efficacy reported in clinical trials to date, looking at response as a single agent as well as studies evaluating combination therapies with HDAC inhibitors.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

In this activity, Dr. Sergio Giralt discusses the role of transplant in light of the new agents that are now available, which patients should be considered for stem cell transplant, and the barriers and challenges that confront patients and their families as they face important treatment decisions.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

Prognostication in AML has become more challenging as each new treatment regimen receives approval. In this activity, Dr. Amir Fathi discusses the current standard of care for risk stratification in AML and how to incorporate genetic testing results in treatment selection. The goal of this activity is to improve the knowledge and competency of oncology providers in the safety and efficacy of IDH Inhibitors and their role in the treatment of AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

In this activity, you will view video highlights from the 2019 American Society of Hematology (ASH) Annual Meeting. Experts share their insights on a variety of abstracts, covering topics including, but not limited to: IDH2 mutations, quizartinib in patients with relapsed/refractory (R/R) AML, and venetoclax-based therapies in newly-diagnosed and R/R AML.

Chapter 1: Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory AML - Jorge E. Cortes, MD

Chapter 2: Encouraging Clinical Profile of IMG632 and Updated Results from Venetoclax in Combination with Idasanutlin - Naval Daver, MD

Chapter 3: PRIMULA and ASCERTAIN: Updates from Two Potentially Practice-changing Studies - Guillermo Garcia-Manero, MD

Chapter 4: Mutations in Patients with R/R AML Who Received Gilteritinib or in Response to Quizartinib or Salvage Chemotherapy - Alexander Perl, MD

Chapter 5: Relapse Following Ivosidenib Monotherapy in Patients with IDH1 Mutant R/R AML and Enasidenib plus Azacitidine Improves CR and Overall Response Rates in ND AML - Eytan M. Stein, MD

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grant from Celgene Corporation and Helsinn.

The role of IDH1/2 inhibitors are established as treatments for relapsed/refractory (RR) AML, and the IDH1 inhibitor ivosidenib has recently been approved by the FDA for adults aged 75 years or older with newly diagnosed AML who have an IDH1 mutation as detected by an FDA-approved test or are ineligible for intensive induction chemotherapy. In this activity, Dr. Eytan Stein discusses the rationale for studying IDH1/2 inhibitors in both newly diagnosed AML and RR AML, including the clinical implications that come with these approvals.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

Managing high-risk AML has continued to be a challenge for clinicians, not only in older patients but younger patients as well. In this activity, Dr. Ravandi covers novel agents both alone and in combination that are being developed as therapeutic options for patients with high-risk AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.

The medical landscape of AML is rapidly evolving, as evidenced by updated practice guidelines and the World Health Organization revised diagnostic and prognostic criteria. The challenges facing clinicians in remaining current with the latest evidence in AML represents a major need. As new agents are used in the clinical practice setting, and as emerging therapies reach the likelihood of approval, it will be increasingly important for healthcare practitioners to be aware of the data and engage in education which will allow them to confidently interpret the evidence for real-world practice. This activity will provide clinicians with evidenced-based, and practical expert led instruction on developing optimal treatment strategies for your patients with AML.

This activity was previously presented on September 11, 2019 to a live audience during the 2019 SOHO Annual Meeting in Houston, Texas.
Please note: If you attended the live meeting or simulcast viewing, you are ineligible to receive an additional 1.25 contact hours of credit and may not re-submit for credit previously awarded.

Provided by MediCom Worldwide, Inc.
Supported by educational grants from Agios Pharmaceuticals, Inc., Astex Pharmaceuticals, Jazz Pharmaceuticals plc, and Pfizer Inc.

Strategies for managing patients with relapsed/refractory (R/R) AML continue to evolve as new therapies are introduced into the treatment armamentarium. In this activity, Dr. Alexander Perl describes important considerations and challenges that can impact the care of patients with R/R AML and strategies for determining eligibility for stem cell transplantation. Efficacy and safety data regarding current and emerging pharmacologic treatment options for R/R AML are also reviewed.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals

Many prognostic factors are related to the sensitivity of acute myeloid leukemia to currently available therapies. In this activity, Dr. Harry Erba focuses on antecedent hematologic disorders leading to secondary AML and treatment-related AML. He also explains the standard of care for incorporating therapeutic agents into the treatment of patients with secondary AML and treatment-related AML in your clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals.

In this activity, view video highlights from the 2018 American Society of Hematology (ASH) Annual Meeting and listen as experts share their insights on a variety of abstracts, covering topics including, but not limited to: the efficacy and safety of emerging drugs for relapsed/refractory AML; venetoclax in combination for older AML patients who are ineligible for intensive chemotherapy; and the status of various clinical trials.

Chapter 1: Improving Outcomes in R/R AML: Can Unique Combinations of Novel Agents Impact Prognosis? Early Trial Results of Venetoclax + Idasanutlin and Azacitidine + Nivolumab, Azacitidine + Ipilimumab

Chapter 2: Maximizing Efficacy Across the Spectrum of AML: Early Clinical Trial Results of the FLT3 Inhibitor Quizartinib in Newly Diagnosed and R/R AML

Chapter 3: The Clinical Challenge of Older AML Patients Ineligible for Intensive Chemotherapy: Clinical Trial Results of Venetoclax in Combination with Cytarabine and HMAs

Chapter 4: The Emerging Role of Bispecific Antibodies in AML: Promising Early Trial Results

Chapter 5: Ivosidenib and Enasidenib: Do These IDH Inhibitors Impact Survival in Newly Diagnosed AML Patients?

Chapter 6: Newer Generation Antibody-Drug Conjugates: Is There a Future For Monotherapy and/or Combination Strategies with Oral Agents in AML?

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Daiichi Sankyo, and Helsinn Healthcare SA, and Jazz Pharmaceuticals.

Treatment options for younger patients with newly diagnosed AML are expanding, with the recent approvals of several targeted therapies, as well as clinical trials investigating novel agents. In this interview, Dr. Pinkal Desai discusses the diagnosis and prognosis of younger people with AML, current standards of care, and key data from clinical trials assessing novel targeted combination therapies to optimize the management of this unique patient population.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals

With the treatment landscape for acute myeloid leukemia (AML) continuing to expand, it is critical for physicians to be up-to-date on the emerging role of FDA-approved therapies and combinations as well as those being explored in clinical trials. In this activity, Dr. Amir Fathi describes the emerging role of FLT3 and IDH1/2 inhibitors in AML. He also discusses the treatment paradigm for non-intensive, upfront therapy when caring for older or less functionally robust patients with the disease.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals

Editor’s Note: Following the release of this activity, on November 21, 2018 the FDA approved venetoclax in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed AML patients who are age 75 years or older, or have comorbidities that preclude use of intensive induction chemotherapy.

AML is typically a disease of older adults, a group of patients that fares significantly worse than their younger counterparts. As the treatment landscape for AML continues to expand, clinicians must have a practical, working knowledge of important considerations when managing older patients to individualize therapy. In this activity, Dr. Farhad Ravandi discusses strategies to optimize treatment in older AML patients, describing how age is a factor in AML and outlining emerging approaches to managing this difficult-to-treat patient population.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals

Editor’s Note: Following the release of this activity, on November 21, 2018 the FDA approved venetoclax in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed AML patients who are age 75 years or older, or have comorbidities that preclude use of intensive induction chemotherapy.

New therapies are helping to improve survival in patients with AML who present with FLT3 mutations. In this activity, Dr. Perl reviews the current status and future direction of first- and second-generation FLT3 inhibitors, both approved and in clinical trials.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals

Evolving Paradigms in AML: Navigating New Therapeutic Opportunities in the Frontline and Relapsed Settings is a digitally captured archive of a live independent satellite symposium held on September 13 during the SOHO 2018 Meeting. The medical landscape of AML continues to evolve, as evidenced by the approval of five new agents since April 2017 and the anticipated approval of additional novel agents in the very near future. An explosion of clinical trials and updated practice guidelines – coupled with a multitude of therapies in late-stage development – has created the vast challenge of staying up-to-date with clinical evidence impacting practice and patient outcomes. Our experts provide a high-level overview of the latest data from newly diagnosed to relapsed disease, focusing on the most current therapeutic landscape.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals.

As the treatment landscape for both newly diagnosed and relapsed/refractory AML continues to expand, clinicians must have a practical, working knowledge of the efficacy and safety data of recently approved therapies beyond FLT3 inhibitors as well as novel agents in clinical development. In this activity, Dr. Daniel Pollyea describes several of the current and emerging therapies that are being investigated in clinical trials as treatment for AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals

In this activity, view video highlights from the 2018 European Hematology Association (EHA) Annual Congress and listen as experts share their insights on a variety of abstracts covering topics including, but not limited to: the efficacy and safety of emerging drugs for newly diagnosed and relapsed/refractory AML; monotherapy and combination treatments in clinical trials; and sequencing of therapy for relapsed/refractory disease.

• Chapter 1: Key Findings in AML: An Overview
• Chapter 2: Quizartinib: An Emerging Treatment Option for Relapsed/Refractory FLT3 ITD AML
• Chapter 3: Strategies for Achieving Durable Responses in Elderly AML Patients
• Chapter 4: Enasidenib in Newly Diagnosed and Relapsed/Refractory Mutant IDH2-positive AML
• Chapter 5: Emerging Combinations and Therapies in Newly Diagnosed and Relapsed/Refractory AML

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., and Helsinn Healthcare SA

In this activity, participants will hear key highlights of several significant scientific updates in acute myeloid leukemia (AML) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Experts will share insights on a variety of abstracts covering topics including: treatment selection strategies, targeted combination therapies, immunotherapies, and novel agents for both newly diagnosed and relapsed/refractory AML patients. Don’t miss this opportunity to see how the future of treatment in AML is evolving, and how these changes may positively impact patient outcomes.

• Chapter 1: Key Findings in AML: An Overview
• Chapter 2: New Data from the Ongoing Phase 1 Study Evaluating Single-Agent IDH1 Inhibitor AG-120 in Relapsed/Refractory AML
• Chapter 3: Two Phase 3 Trials in Progress: HDAC Inhibitor Pracinostat in Combination with Azacitidine; NEDD Inhibitor Pevonedistat + Aza
• Chapter 4: Post hoc Analysis of Clinical Activity of Quizartinib in Patients with Prior TKIs
• Chapter 5: IDH1 and IDH2 Inhibitors in Combination with Aza in the Upfront Setting
• Chapter 6: The Role of Nivolumab in Maintenance Therapy; BCL-2 Inhibitor Studies in Newly Diagnosed AML; Impact of NGS on Therapy Selection

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., and Helsinn Healthcare SA

The treatment landscape for acute myeloid leukemia (AML) continues to evolve with several recent FDA approvals of novel treatment options, including an isocitrate dehydrogenase 2 (IDH2) inhibitor. Mutated IDH2 is present in 8-19% of patients diagnosed with AML, making it an important target to treat when managing the disease. View this activity and hear how Dr. Carraway discusses the role of IDH2 inhibitors in the diagnosis, prognosis, and treatment of patients with IDH2-mutated AML. She will outline a treatment plan for managing these patients in the relapsed or refractory setting, taking into consideration patient selection, proper administration, and potential adverse events. Furthermore, Dr. Carraway will identify the latest updates in emerging data related to the safety and efficacy of IDH2 inhibitors currently in clinical trials.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., and Helsinn Healthcare SA.

In this activity, participants will learn about key highlights of the latest and most impactful data in acute myeloid leukemia (AML), presented at the 2017 American Society of Hematology (ASH) Annual Meeting.

Chapter 1: Developments in FLT3 Inhibitors, Chemotherapy, and Small Molecule Inhibitors

Chapter 2: Pracinostat with Azacitidine in Elderly Patients

Chapter 3: CPX-351 vs 7+3 in Older Adults: Efficacy and Safety Reported in Clinical Trial

Chapter 4: Biomarker-driven Treatments: Ivosidenib, Enasidenib, and Sy-1425

Chapter 5: Combination Therapies Involving Gilteritinib and Venetoclax

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Due to the recent advances in the knowledge of molecular profiles, karyotyping, and the physiopathology of the disease, we are able to classify AML into different categories: favorable, intermediate, and adverse; all which have implications into the treatment and the outcome of the disease. View this activity and hear how Dr. Jabbour outlines the evolving treatment landscape and the identified subsets of AML that will help set the stage for treatment selection and sequencing. He will share with you an overview of the newly approved and emerging treatment options in clinical trials and offer insights into defining a new treatment plan in the era of expanded opportunities.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

There is a significant unmet need in existing treatment paradigms for patients with acute myeloid leukemia (AML) due to poor survival and intolerability to cytotoxic chemotherapy, especially for a generally older patient population. Hypomethylating agents (HMAs) have demonstrated a benefit in patients with AML, especially those who require less aggressive therapy, but there is a need for improved efficacy and survival outcomes. In this activity, participants will learn about HMAs in existing treatment paradigms, as well as the investigational landscape of novel therapies in combination with HMAs, and their potential impact on treatment outcomes for patients with AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

In this activity, participants will learn about key highlights of the latest and most impactful data in acute myeloid leukemia (AML), presented at the 2017 European Hematology Association (EHA) 22nd Congress.

Chapter 1: Combination Therapy with Novel Agents and Chemotherapy Improves Survival in Diverse Subsets of AML Patients

Chapter 2: Safety and Efficacy of Enasidenib in Patients with Mutant-IDH2 Relapsed AML

Chapter 3: Improving Efficacy of Mutation-specific Therapeutic Options in AML: Emerging Data and Novel Agents

Chapter 4: Improved Efficacy, Safety with CPX-351 in Older Adults with Newly Diagnosed Therapy Related AML

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Acute myeloid leukemia (AML) is generally a hematologic malignancy of older adults, with approximately 60% of newly diagnosed AML patients being 60 or older. Older patients pose unique therapeutic challenges that have been largely unmet to date. This activity will review and discuss decision-making strategies outlining when and how to treat this patient population in your practice. In addition, Dr. Nazha will provide an overview of the current treatment paradigms available, as well as agents currently approved or under investigation which may have a potential role in the outcome of the older patient with AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

This activity has been developed from a live symposium held in conjunction with a clinical oncology meeting held in June 2017, focusing on the newest advancements in acute myeloid leukemia (AML). Drawing upon both clinical trial data and analysis of case vignettes, a distinguished faculty panel discusses not only new and emerging strategies in the diagnosis, prognosis, and treatment of AML, but also how these critical new advances will change practice in the near future.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Astellas, Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, and Jazz Pharmaceuticals.

In acute myeloid leukemia (AML), several epigenetic pathways have been implicated in disease pathogenesis, including DNA methylation, histone acetylation, and histone methylation. Ongoing research is focusing on these epigenetic pathways for the development of novel agents and regimens across the disease lifecycle. Join Dr. Ravandi as he describes the molecular and cellular processes that are driving oncogenesis in AML, how the mechanisms of action of several new and emerging agents in AML target specific genetic mutations, and the critical implications for clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Helsinn Healthcare SA, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.